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β-Methylphenylethylamines are positional isomers of amphetamines and have been discovered in 
sporting supplements. Although the fragmentation of the β-methylphenylethylamine and N-methyl-
β-methylphenylethylamine in GC-EI-MS systems is significantly different to their amphetamine 
and methylamphetamine isomers, under electrospray ionisation commonly used in LC-MS systems, 
the fragmentation of each of the isomeric pairs is almost identical. The similarities in fragmentation 
make it possible for the misidentification of the β-methylphenylethylamines as the illicit 
amphetamines. It is proposed that the similarities are due to a fragmentation pathway involving a 
common phenonium ion intermediate. By careful control of fragmentation energies in LC-MS-MS 
systems and/or close examination of the relative abundances of product ions formed by collision 
induced dissociation (qualifier ratios) it is possible to distinguish the β-methylphenylethylamines 
from the amphetamines, even if significant retention time separation is not achieved. In LC-ESI-
QTOF systems the mass spectra of the β-methylphenylethylamines are identical to their 
amphetamine isomers. In such systems retention time separation of the isomers is critical to avoid 
misidentification. During this study β-methylphenylethylamine and N-methyl-β-
methylphenylethylamine have been identified in commercially available sporting supplements and 










 Dietary supplements, including weigh loss, "pre-workout" and "sporting" supplements have 
received significant attention in recent years due to the inclusion of compounds with potential 
stimulant properties in their formulations. In many cases the ingredients listed on these products do 
not specifically name the included stimulants. This case was no better highlighted than by Cohen et 
al. who identified the amphetamine derivative N,α-diethylphenylethylamine in the supplement 
Craze.[1-2] Numerous athletes have tested positive to this stimulant,[1, 3] which is banned by the 
World Anti-Doping Agency (WADA).[4] 
 
Another such class of compounds that have been detected in sporting supplements are the β-
methylphenylethylamines, specifically β-methylphenylethylamine (1),[5-8] N-methyl-β-
methylphenylethylamine (2)[9-10] and N,N-dimethyl-β-methylphenylethylamine.[11] During the mid-
20th century these compounds were explored for their medicinal vasopressor and sympathomimetic 
properties, particularly 2.[12-14] Recent interest in the case of 2 has focused on its use as a 
performance-enhancing drug in sport (doping), and in the case of 1 its appearance in dietary 
supplements.[5-7, 15] The compounds 1 and 2 are positional isomers of amphetamine (3) and 
methylamphetamine (4), respectively, which are α-methylphenylethylamines. These compounds 
have potential stimulant properties and are banned by WADA (2 specifically listed as 
phenpromethamine).[4] Two different issues are present with these compounds, firstly, they have 
been detected in supplements even though they do not appear on the ingredients list. For example, 
studies by Pawar et al., and more recently Cohen et al., have highlighted that fact that a number of 
supplements claiming to contain an "Acacia rigidula extract" contain β-methylphenylethylamine 
(1).[5, 7] The second, and significant, issue relating to the β-methylphenylethylamines is that they 
appear to behave almost identically to their isomeric amphetamines under LC-MS (liquid 
chromatography-mass spectrometry) conditions. A review of recent articles focused on screening 
and confirmation methods for doping control that include 2 in their compound lists highlight the 
potential problems. In the most part these publications have used LC-MS based instrumentation 
with either HPLC (high performance liquid chromatography) or UHPLC (ultra high 
performance/pressure liquid chromatography) systems coupled with a variety of mass spectrometer 
(MS) detectors [e.g. quadrupole-time-of-flight (QTOF), time-of-flight (TOF), orbitrap, triple-
quadrupole (QqQ)]. The data provided in these publications is varied: where parent or product ion 
data is presented for 2 and 4 it is identical (parent m/z 150, product ions m/z 119 and 91);[16] in a 
number of cases no retention time data for 2 and 4 is provided;[16] where retention time details are 
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provided for 2 and 4 in some cases it is very similar (ΔRT 0.01-0.04 min.),[17-20] or identical![21] Of 
these doping-based papers, only one provided discussion about the need to achieve retention time 
separation to distinguish 2 and 4.[19] Interestingly, one paper reported the identification of 2 when 
testing a screening method with an automated search capacity using a certified reference material 
containing methylamphetamine (4).[22] When GC-MS (gas chromatography-MS) techniques are 
used for doping analysis then the fragmentation ions for 2 and 4 are different.[23] A number of 
recent publications have highlighted the similarity of the fragmentation of β-
methylphenylethylamine (1) and amphetamine (3) by electrospray ionisation (ESI)-mass 
spectrometry.[5-6, 15] The parent ions for 1 and 3 under LC-ESI-MS conditions (ESI-Q-orbitrap, ESI-
QTRAP or ESI-QTOF) have a m/z of 136 (M+1), and both produce product ions with m/z values of 
119, 91 and 65 depending on applied collision energy,[5-6, 15] in almost identical intensities.[5-6] 
Pawar et al.[5] and Vaclavik et al.[15] reported retention time separations of 1 and 3, however 
baseline-separation could not be achieved. A more recent UPLC method reported by Chołbiński et 
al. achieved ca. 0.5 min. separation of 1 and 3.[6] None of above publications have provided an 
explanation to the mass spectral similarity for the β-methylphenylethylamines and their isomeric 
amphetamines. The similarities in mass spectra and possible similarities of retention times, 
highlighted above, leads to the possibility of miss identifying β-methylphenylethylamines as their 
isomeric amphetamines. 
 
Within our laboratories we routinely quantify illicit amphetamines in urine, blood and oral fluid 
matrices, for the purposes of post mortem toxicology, drugs in driving offenses, and work-place 
testing. Our GC-MS, LC-ESI-QqQ and LC-ESI-QTOF analyses of these analytes follow on from 
liquid-liquid extraction, solid-phase extraction (SPE), and extractive-benzoylation methods. In this 
paper we explore the mass spectral and chromatographic properties of the β-
methylphenylethylamines 1 and 2 both derivatised and underivatised and provide an explanation for 
the observed similarities in the fragmentation of these compounds with their isomeric 
amphetamines 3 and 4 under ESI-CID (electrospray ionisation - collision induced dissociation) 
conditions. We also present some methods for distinguishing these compounds using ESI-QqQ 
systems, crucially by the careful analysis of qualifier ratios and control of collision energies. 
 
During the review of this manuscript the US Food and Drug Administration (FDA) released a 
statement on the presence of β-methylphenylethylamine (1) in dietary supplements, and highlighted 
action taken by the FDA towards a number of manufacturers of supplements containing β-
methylphenylethylamine (1).[8] In Australia, dietary supplements including "sports-related food 
products" are regulated by Food Standards Australia New Zealand, through the Australia New 
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Zealand Food Standards Code. With regard individual compounds that may be found in 
supplements, the Therapeutic Good Administration (TGA) regulates medicines and poisons and 
maintains the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Though 
they do not regulate food products, individual compounds discovered in supplements may be 
banned by the TGA and added as a poison to the SUSMP.[24] 
 
Methods  
Standards of amphetamine and methylamphetamine (both D0 and D5) were purchased from 
Cerilliant, while samples of β-methylphenylethylamine (β-methylphenethylamine) and N-methyl-β-
methylphenylethylamine [methyl-(2-phenyl-propyl)-amine] were purchased from Sigma-Aldrich. 
Sporting and dietary supplements BMP Labs Lipodrive tablets (received mid-2013), BMP Labs 
Lipodrive powder (received early-2014) and APS Mesomorph 2.0 (received early-2014), were all 
purchased locally. Table 1 lists the ingredients of these supplements, based on their labelling. 
 
Extractive benzoylation was performed with pentafluorobenzoyl chloride (PFB-Cl) following 
standard procedures.[25] Both derivatised and underivatised samples were reconstituted in methanol 
or methanol:pH 9 buffer (70:30) prior to analysis on an Agilent 1200 Series HPLC coupled to an 
Agilent 6410 Triple Quadrupole Mass Spectrometer. QTOF analysis was performed on an Agilent 
1260 Infinity HPLC coupled to an Agilent 6540 QTOF Mass Spectrometer. The following buffers 
were used for chromatographic analysis: 10 mM ammonium formate buffered to pH 9 with 
ammonia solution ("pH 9 buffer"); 10 mM ammonium formate buffered to pH 3 with formic acid 
("pH 3 buffer"). Electron ionisation mass spectra were obtained on an Agilent 6890 GC-5975 MSD 
system with a m/z range of 40 - 400. 
 
Preparation of supplement solutions for analysis: Supplement powders were dissolved in water 
based on the label instructions. The resulting solutions were then diluted 100 times with water. A 
Lipodrive tablet was dissolved in 500 mL water and the resulting solution was diluted 100 times 
with water. The diluted supplement solutions were extracted as per the extractive benzoylation 
(derivatised) and oral fluid extraction (underivatised) procedures below. 
 
Extraction of oral fluid and supplement samples (underivatised): To 0.2 mL of oral fluid (either neat 
or with buffer/solvents from Dräger or Cozart/Alere oral fluid collection devices) was added 10 μL 
of a mixed internal standard solution containing D5-amphetamine and D5-methylamphetamine (1 
μg/mL), 0.2 mL of concentrated ammonia solution (28%) and 5 mL cyclohexane. The mixture was 
vortexed for 5 mins, centrifuged and the organic phase separated. To the organic phase was added 1 
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drop of a methanolic HCl solution (5% 0.1 M HCl in methanol) and the mixture was evaporated to 
dryness without heat. The residue was reconstituted in 100 uL methanol. Samples were analysed on 
the Agilent 6410 Triple Quadrupole Mass Spectrometer in MRM (multiple reaction monitoring) 
mode, using a pH9 buffer/methanol elution solvent. Fragmentor voltage 110 V; MRM Transitions 
m/z 150 -> m/z 119 (CE 10 V), m/z 150 -> m/z 91 (CE 14 V); m/z 136 -> m/z 119 (CE 9 V); m/z 136 
-> m/z 91 (CE 14 V). 
 
Extractive benzoylation (derivatisation) of urine and supplement samples: To 0.2 mL of solution 
(urine or supplement solution) was added 0.2 mL of concentrated ammonia solution (28%), 1 mL 
water and 5 mL cyclohexane solution containing D5-amphetamine and D5-methylamphetamine 
(100 ng per 5 mL). While mixing, 75 μL of a pentafluorobenzoyl chloride solution (5% in butyl 
chloride) was added. After mixing for 5 minutes the organic phase was separated, and then 
evaporate to dryness without heat. The residue was reconstituted in 100 uL methanol:pH 9 buffer 
(70:30). Samples were analysed on the Agilent 6410 Triple Quadrupole Mass Spectrometer in 
MRM mode, using a pH9 buffer/methanol elution solvent. Fragmentor voltage 110 V; MRM 
Transitions m/z 344 -> m/z 119 (CE 5 V), m/z 344 -> m/z 91 (CE 5 V); m/z 330 -> m/z 119 (CE 5 
V); m/z 330 -> m/z 91 (CE 5 V). 
 
Chromatographic conditions. 
Underivatised (pH 9): pH 9 buffer : methanol; flow rate 0.5 mL/min; 50 °C  pH 9 buffer 85% 0-1 
min, 15% 3 min, 5% 4-7 min, 85% 7.1-12 min; using a Phenomenex Kinetex 2.6 μm, 100 x 3.0 mm 
C18 column. 
Derivatised:  pH 9 buffer : methanol; flow rate 0.5 mL/min; 50 °C ; pH 9 buffer 60% 0-1 min, 15% 
2 min, 5% 3-5 min, 60% 5.1-10 min; using a Phenomenex Kinetex 2.6 μm, 100 x 3.0 mm C18 
column. 
Underivatised (pH 3): pH 3 buffer : acetonitrile; flow rate 0.6 mL/min; 30 °C ; pH 3 buffer 90% 0-2 
min, 80% 4 min, 5% 6.7-10 min, 90% 10.1-13 min; using a ACE Excel 3 SuperC18 3 μm, 100 x 3.0 
mm column.  
 
Comparing qualifier ratio data obtained from LC-ESI-QqQ data: Since absolute qualifier ratios can 
vary with changes in the tuning of the QqQ mass spectrometer we determined percentage 
differences of qualifier ratios of the β-methylphenylethylamines (1 or 2) compared with the relevant 
amphetamine standards (3 or 4). For individual sets of data the qualifier ratios of each amphetamine 
standard was averaged, covering the full calibration range. This average value was used as the 




Results and Discussion 
 
The structures of the β-methylphenylethylamines 1 and 2 and the amphetamines 3 and 4 are 
different enough to expect some significant fragmentation differences, based on conventional 
fragmentation pathways. When electron ionisation (EI) mass spectra, obtained from a GC-MS, were 
compared the differences were obvious (see Figure 1 as an example). The EI fragmentation of 
amphetamine (3) displayed the ions m/z 134, 120, 91, 64 and 44, whereas β-
methylphenylethylamine (1) displayed numerous fragments, including a m/z 105 ion (and an intense 
m/z 30 ion if the mass spectrum is measured lower than m/z 40, see below). Conventional 
fragmentation pathways, with formation of a benzylic cation (or corresponding tropylium ion) 
readily explain the formation of the m/z 91 ion for 3 and the m/z 105 ion for 1. The EI mass spectra 
for the N-methyl analogues 2 and 4 displayed analogous differences, including a m/z 105 ion for 2 
(see Supporting Information). The EI mass spectra of the pentafluorobenzoyl (PFB) derivatised 
amines showed similar key differences with m/z 105 ions for the β-methylphenylethylamines (1-
PFB and 2-PFB) and m/z 91 ions for the amphetamines (3-PFB and 4-PFB) (see Supporting 
Information, Figures S2 and S3), again consistent with conventional fragmentation pathways. Each 
of the amines, both derivatised and underivatised, displayed ions in the EI mass spectra that were 
consistent with the formation of iminium ions (R2C=NR2
+). In the case of the underivatised amines 
1 - 4 the iminium ion is the most intense ion that forms following electron ionisation. For β-
methylphenylethylamine (1) the iminium ion m/z 30 does not appear in Figure 1 as the instrument 
was set to measure m/z values greater than m/z 40, however, in the NIST mass spectral library the 
mass spectrum for 1 displays the m/z 30 ion as the base peak, with the next most intense ion being 
m/z 91 at <20% relative intensity.[26] Other than the absence of the ions less than m/z 40 the mass 
spectrum of 1 in Figure 1 is identical to that in the NIST mass spectral library.[26] The iminium ions 
for amphetamine (3) and methylamphetamine (4) are m/z 44 (Figure 1(b)) and m/z 58 (Figure S1(b)) 
respectively. These spectra are also identical to the spectra in the NIST mass spectral library.[26] In 
the case of N-methyl-β-methylphenylethylamine (2) the iminium ion is m/z 44 (Figure S1(a)). The 
ions that are consistent with the formation of iminium ions for the derivatised amines 1-PBF (m/z 
224), 2-PFB (m/z 238), 3-PFB (m/z 238) and 4-PFB (m/z 252) were also present in their mass 
spectra (see Supporting Information). The EI-MS spectra for 3-PFB and 4-PFB presented in 
Figures S2 and S3 are consistent with published data.[27] As a consequence of the EI mass spectra it 
is easy to distinguish the β-methylphenylethylamines 1 and 2 from their isomeric amphetamine 3 
and 4 by conventional GC-MS (derivatised or underivatised).  
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When the β-methylphenylethylamines 1 and 2 were fragmented under electrospray ionisation (ESI) 
conditions the ions that were formed were very different from those under EI conditions. 
Fragmentation of 1 or 2 using a ESI-QqQ with collision-induced dissociation (CID) of 5 V afforded 
product ions with only m/z values of 119 and 91 (see Figure 2(a)(i) and Figure S4(a)(i) in 
Supporting Information). These fragmentation ions were identical to those formed from the 
amphetamines 3 and 4 (see Figure 2(a)(ii) and Figure S4(a)(ii) in Supporting Information). The m/z 
91 and 119 ions were also observed in the ESI-QqQ CID fragmentation of the pentafluorobenzoyl 
(PFB) derivatised amines 1-PFB , 2-PFB, 3-PFB and 4-PFB (see Figure 2(b) and Figure S4(b) in 
Supporting Information). In the case of the derivatised amines, the additional ions formed from 
fragmentation, m/z 212 and 226, involve the pentafluorobenzamide moiety. When the CID energy 
was increased then a product ion with an m/z of 65 formed in the CID of 1, 2, 3 and 4 (and their 
PFB derivatives). The observation that 1 and 3 formed the product ions m/z 119, 91 and 65 
following CID is consistent with the MS/MS spectra reported by Pawar et al. using a LC-Qtrap 
system[5] and Chołbiński et al. using LC-QTOF and LC-tandem MS systems,[6] although the 
relative intensities of the ions differed due to different CID energies. Interestingly, no m/z 105 was 
observed in the ESI-CID of the β-methylphenylethylamines 1 and 2, either underivatised or 
derivatised (i.e. 1-PFB and 2-PFB) (cf. EI-mass spectra in Figures 1, S1 and S2). Selective 
fragmentation by CID of the m/z 119 ion for each of the analytes examined afforded a 91 product 
ion. None of the ESI-CID spectra for the derivatised (1-PFB - 4-PBF) or underivatised (1 - 4) 
amines displayed ions consistent with the formation of iminum ions. 
 
The observed similarities in the ions that formed from the ESI-CID fragmentation of the β-
methylphenylethylamines 1 and 2 and the amphetamines 3 and 4 (and their PFB derivatives) 
suggested a very different fragmentation process than those that occurred under EI conditions. We 
believe the similarities arise from a common fragmentation pathway involving the formation of a 
phenonium ion, in the first instance, following an intramolecular cyclisation fragmentation process 
(Scheme 1). Similar phenonium ions have been proposed in the fragmentation of phenylalanine 
derivatives[28] and gas-phase rearrangement mechanisms involving phenylpropanols.[29] Even 
though it was possible to measure the parent ion -> m/z 91 "transition", we believe that this 
fragmentation process goes via the phenonium ion (m/z 119) which further fragments to the m/z 91 
ion. 
 
Closer examination of the relative abundance (i.e. qualifier ratios: m/z M+1-> m/z 119 vs m/z M+1-
> m/z 91) of the product ions that formed for each of the isomeric pairs of compounds: β-
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methylphenylethylamine (1) and amphetamine (3); and N-methyl-β-methylphenylethylamine (2) 
and methylamphetamine (4), indicated a potential method for discrimination of these compounds. 
When the pentafluorobenzoyl derivatives 1-PFB, 2-PFB, 3-PFB and 4-PFB were fragmented with 
a fragmentor voltage of 100 V and a CID energy of 15 V the relative abundances of each of the 
major transitions m/z M+1 -> m/z 119 and m/z M+1-> m/z 91 were very similar (see Figure 3(a)). In 
the case of 1-PFB the ratio of the m/z 330 -> m/z 91 and m/z 330 -> m/z 119 transitions were within 
5-12% of the ratio for the equivalent transitions for the amphetamine isomer 3-PFB, across a 
significant calibration range (10-1250 ng/mL). For 2-PFB the ratio of the m/z 344 -> m/z 91 and m/z 
344 -> m/z 119 transitions were not as close, but were still within 17-22% of the ratio for the 
equivalent transitions for the amphetamine isomer 4-PFB. The similarities of the "qualifier ratios" 
is of significance since commonly accepted guidelines for the identification of compounds by mass 
spectrometry in a forensic context suggest one criteria for confirming the identification of 
compound is that the qualifier ratios are within 20% of that of a standard.[30-31] The information 
presented above clearly indicates the potential for the miss identification of β-
methylphenylethylamines as their isomeric amphetamines (based on their mass spectra). When the 
same transitions were examined with a lower CID energy of 5 V the relative abundances of each of 
the major transitions became significantly different between the β-methylphenylethylamine and the 
amphetamines (Figure 3(b)). The ratios of the m/z 330 -> m/z 91 and m/z 330 -> m/z 119 transitions 
for 1-PFB and the m/z 344 -> m/z 91 and m/z 344 -> m/z 119 transitions for 2-PFB were greater 
than 30% (30-40%) different from the ratios for the equivalent transitions for the amphetamine 
isomers 3-PFB and 4-PFB. Using a lower CID energy allowed for these compounds to be 
distinguished based on the commonly accepted guidelines mentioned above. The use of a lower 
CID to differentiate the β-methylphenylethylamines from the amphetamines is also consistent with 
the proposed fragmentation pathways in Scheme 1. The amount of energy required to form the 
phenonium ion intermediate would be subtly different for the two different classes of compounds. 
With low CID energies not all of the parent ions would fragment to the m/z 119 ion, and for each of 
the different compounds this would vary. It is this variation that was critical for the differences in 
the qualifier ratios. For instance, when higher CID energies were used, it was possible to also 
examine the m/z M+1 -> m/z 65 transition for each of the four compounds. Through comparison of 
the m/z M+1 -> m/z 91 vs m/z M+1 -> m/z 65 transitions for each of the isomeric pairs of 
compounds, it was not possible to distinguish the β-methylphenylethylamines from the 
amphetamines, however, if the m/z M+1 -> m/z 119 transition (with low CID energy) was used 
versus either of the m/z M+1 -> m/z 91 or m/z M+1 -> m/z 65 transitions (with high CID energy) 




Unlike the derivatised compounds, decreasing the CID energies to 5 V for the analysis of the 
underivatised amines 1 - 4 did not produce a significant change in the relative abundances of the 
m/z M+1 -> m/z 119 and m/z M+1 -> m/z 91 transitions. For β-methylphenylethylamine (1), the 
ratio of the m/z M+1 -> m/z 119 and m/z M+1 -> m/z 91 transitions, determined with CID energies 
of 9 and 14 V respectively, was 17-23% different than the equivalent ratio for amphetamine (3), 
across a calibration range of 10-500 ng/mL (Figure 3(c)). This difference in ratio was significant 
enough to distinguish 1 and 3 relatively easily, provided the qualifier ratio ratios were examined 
closely. However, in the case of N-methyl-β-methylphenylethylamine (2) the equivalent ratio was 
typically only 9-15% different from that of methylamphetamine (4). In this case the possibility of 
the misidentification of N-methyl-β-methylphenylethylamine (2) as methylamphetamine (4), if 
retention time separation is not achieved, becomes significant. 
 
Other than their mass spectral features, the other key aspect in the identification of compounds by 
LCMS is retention time. Due to the similarities in the structures of 1 and 2 with their amphetamine 
isomers 3 and 4 it is possible that their retention times could also be very similar. In our own studies, 
using pH 9 buffer-methanol based gradient elution programs the retention times of the β-
methylphenylethylamines and the amphetamines were very similar, both derivatised and 
underivatised (Figure 3). Other researchers have also identified this problem, and suggested 
solutions with pH 3 solvent systems and particular columns.[5-6] We could obtain full baseline 
separation of the underivatised amines with a pH 3 buffer-acetonitrile gradient program (Figure 4). 
Analysis of the qualifier ratio data obtained from the pH 3 buffer-acetonitrile separation did not 
indicate a significant change in the relative qualifier ratios between the β-methylphenylethylamines 
and the amphetamines when compared to the data (above) obtained from the pH 9-methanol system. 
When investigating the derivatised compounds we could not adequately separate the isomeric pairs 
of pentafluorobenzoyl-derivatised amines using various chromatographic systems, including pH 3 
buffer-acetonitrile, pH 3 buffer-methanol and pH 9 buffer-acetonitrile gradient programs, in 
addition to the pH 9 buffer-methanol gradient program detailed in the methods section. 
 
There is significant interest in using LC-ESI-QTOF systems as a "one-stop" screening tool across 
many areas of analytical chemistry, e.g. post mortem toxicology, work place testing and doping 
control. Due to the interest in this technique we examined the capability of the Agilent QTOF 
system to distinguish between the isomeric β-methylphenylethylamines and amphetamines. In our 
preliminary efforts we found that the QTOF detector could not distinguish the isomeric pairs (1 vs 3, 
and 2 vs 4). The MS/MS spectra obtained using the conventional 10, 20 and 40 V CID energies 
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were practically identical such that software analysis could not identify any significant differences 
(See Figures S5 and S6 in the Supporting Information). The MS/MS spectra reported here for β-
methylphenylethylamines (1) and amphetamines (3) is similar to that obtained by Chołbiński et al., 
albeit using a different QTOF system.[6] We could only distinguish the isomers if retention time 
separation was first achieved with an appropriate solvent system and gradient program (e.g. Figure 
4). This suggested that only with the inclusion of standards into an analysis batch, or good 
confidence on repeatability of retention times could an LC-ESI-QTOF system reliably distinguish 
between the β-methylphenylethylamines and amphetamines. 
 
During casework within our Forensic Toxicology Section, including drugs in drivers analyses for 
the Western Australia Police and work place testing, we have identified both β-
methylphenylethylamine (1) and N-methyl-β-methylphenylethylamine (2) in multiple oral fluid 
samples (covering an approximate range of <25 - 450 ng/mL) and 1 in a urine sample. It should be 
noted that our quantification of 1 and 2 in these samples was only approximate. These values were 
determined using a calibration based on amphetamine and methylamphetamine. The values have 
been included here since they are above the reporting cut-off of 25 ng/mL for amphetamines used 
by the Western Australian Police and the Australian work place testing standard "Drugs in Oral 
Fluid AS4760-2006". In all cases involving the detection of 1 and 2 in oral fluid or urine samples 
our analyses were perform on samples that had tested "positive" to amphetamines in a saliva or 
urine presumptive "on-site"/"on-roadside" testing device (such as Securetec DrugWipe®, Dräger 
DrugTest® 5000, and Cozart DDS/Alere DDS®2 oral fluid testing devices, or urine drug test cups 
containing test strips). During the course of both casework and this project we have also analysed a 
number of different "fat-burning" and "pre-workout" supplements (see Table 1). In one case, tablets 
of the BPM Labs Lipodrive tested positive to 1, but not 2, despite both compounds being listed in 
the supplement ingredients list, however, in a powder formulation of the same product, with the 
same ingredients list, both 1 and 2 were identified. In a different branded supplement (Mesomorph 
2.0) both 1 and 2 were detected though neither was specified in the ingredient list, however, in this 
case the supplement claimed to contain an "Acacia rigidula extract". Supplements listing "Acacia 
rigidula extract" in the ingredients have been shown to contain 1.[5, 7] Figures S7, S8 and S9 in the 
Supporting Information provide examples of the data obtained from analyses of the supplement 
materials, using LC-QqQ methods (derivatised and underivatised) as well as GCMS data of 
derivatised extracts. Figure S10 (Supporting Information) is an example of data obtained from an 
oral fluid sample analysed using an underivatised method on a pH 9-methanol gradient system, 
highlighting how similar the data for 1 and 2 may appear to 3 and 4. In this example qualifier ratio 
indicated that the oral fluid did not contain the illicit amphetamines 3 and 4.  The analyses of the 
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supplements in this study focused on the detection of 1 or 2 in the materials, and not the specific 




We have proposed a common fragmentation pathway for the β-methylphenylethylamines and 
amphetamines when fragmented in ESI-CID systems. We believe it is this pathway that makes 
isomeric pairs of these classes of compounds nearly indistinguishable by MS detectors commonly 
used in LCMS systems. As a consequence, without careful regard for retention times, and qualifier 
ratios (for MRM analyses) there is a possibility to miss identify β-methylphenylethylamines as 
amphetamines. For QTOF-based systems it is imperative to ensure retention time separation 
between the isomeric pairs β-methylphenylethylamine and amphetamine, and N-methyl-β-
methylphenylethylamine and methylamphetamine as the QTOF analyser could not distinguish the 
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Tables and Figures 
 
Table 1. The components listed on the labels of the supplement products analysed in this study 
 
Product (Manufacturer) Components*  Comments from this study 
Lipodrive 
(BPM Labs, tablets) 
Caffeine (27.5 g), R-beta-
methylphenylethylamine.HCl (1.HCl) (3.4 g), 
green tea (Camellia sinensis) leaf extract (4.8 g), 
methylsynephrine (8.4 g), theobromine (13.5 g), 
N-methyl-B-methylphenylethylamine (2) (2.8 g), 
synephrine.HCl (8.3 g), Naringen (8.3 g), Citrus 
Aurantium (blood orange) extract (8.3 g), 
evodiamine (2.8 g), Yerba mate (5.5 g), 
Phenylethylamine.HCl (3.7 g), taurine (5.5 g) 
 
1 detected; 2 not detected 
Lipodrive 
(BPM Labs, powder) 
Proprietary blend containing: Taurine, caffeine, 
R-beta-methylphenylethylamine.HCl (1.HCl), 
green tea (Camellia sinensis) leaf extract, 
theobromine, N-methyl-B-
methylphenylethylamine (2), Naringen, bitter 
orange, evodiamine, Yerba mate concentrate, 
Phenylethylamine.HCl 
 
1 and 2 detected 
Mesomorph 2.0 
(APS) 
Beta alanine, L-citrulline, arginine alpha 
ketoglutarate, DL-creatine malate, L-taurine, 
creatine nitrate, ascorbic acid, creatinol-O-
phosphate, agmatine sulfate, glucuronolactone, 
caffeine, theobromine, Naringen, Acacia 
Rigidula extract 
 
1 and 2 detected 
* Nutritional information from label (Masses per 100 g where provided). 
Note: The analyses conducted in this study only focused on compounds that may cause interferences in the analysis of 








Figure 1. The electron ionisation mass spectra for (a) β-methylphenylethylamine 1 and (b) 




Figure 2. Product ion scans for: (a)(i) β-methylphenylethylamine 1 (M+1 = m/z 136); (a)(ii) 
amphetamine 3 (M+1 = m/z 136); and the pentafluorobenzoyl derivatives (M+1 = m/z 330) (b)(i) 1-








1 R = H
2 R = CH3
3 R = H
4 R = CH3
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Scheme 1. A proposed common ESI-CID fragmentation pathway for the β-




Figure 3. Chromatograms, with individual ion transitions, for: (a) (i) 1-PFB and 2-PFB , and (ii) 3-
PFB  and 4-PFB , with a 15 V CID energy; (b) (i) 1-PFB  and 2-PFB , and (ii) 3-PFB  and 4-PFB , 
with a 5 V CID energy; and (c) (i) 1 and 2, and (ii) 3 and 4 (see Experimental section for 
chromatographic conditions). Each set of chromatograms (e.g. (i) and (ii)) are on the same retention 
time scale. Below each chromatogram are the ratios of the two transitions (m/z M+1 -> m/z 91 vs. 












Figure 4. Chromatogram showing m/z M+1 -> m/z 119 and m/z M+1 -> m/z 91 transitions, 
separation of the underivatised amines 1-4, and phentermine using a pH 3 buffer-acetonitrile 
gradient. Below the chromatogram are the ratios of the two transitions (m/z M+1 -> m/z 91 vs. m/z 
M+1 -> m/z 119; as a percentage) for each compound. 
 
 
 
 
 
